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Aim: To detect the prevalence and type distribution of human papillomavirus (HPV) in different cytological diagnostic categories.
Materials and methods: Between 2007 and 2010, a total of 1014 liquid-based thin preparations of cervical smears were selected and
classified according to cytology results. HPV DNA polymerase chain reaction (PCR) was also performed using these samples. HPV
DNA-positive samples were genotyped by DNA sequencing.
Results: Of those enrolled in the study, 45.3% were negative cytologically, 36.4% had atypical squamous cells of undetermined
significance, 0.3% had atypical squamous cells preventing the exclusion of a high-grade squamous intraepithelial lesion, 16.8% showed
a low-grade squamous intraepithelial lesion, and 1.3% had an high-grade squamous intraepithelial lesion.
Conclusion: PCR assays showed HPV positivity in 63.0% of cytologically negative and 90.8% of cytologically positive samples. The most
common types of HPV detected were 16, 6, 18, 31, 66, 56, 53, 81, 45, and 62. Of HPV DNA-positive samples, 47.7% were high, 4.7%
were intermediate, and 17.9% were low risk. The high-risk types of HPV detected were 16, 18, 31, 56, 53, 45, 62, 58, 59, 67, 51, 35, 73,
52, 33, 39, 68, and 82.
Key words: Cytology, human papillomavirus DNA, genotype, polymerase chain reaction

1. Introduction
Infections caused by certain viruses have a role in the
pathogenesis of some cancers in humans (1). Cervical
cancer is among the most important causes of cancerrelated death among women worldwide; 500,000 cases
occur annually with a mortality rate of 50%. A strong
causal relationship has been established between infection
with human papillomavirus (HPV) and cervical cancer,
with an estimated 99.7% prevalence of HPV in patients
with cervical cancer (2,3). The prevalence of HPV
infection is 2%–44% worldwide, and there are differences
in prevalence between different societies (4). Generally,
HPV infection prevalence is high among young women
and becomes lower with age (5). Approximately 15
oncogenic HPV genotypes are generally accepted to be the
cause of all cervical cancer (6). Cytological examination
results also have great importance in HPV infections. In
a multicenter study in Turkey involving 33 collaborating
healthcare centers, cervical epithelial abnormalities were
detected in 1.8% of samples, and the prevalence rates of
atypical squamous cells of undetermined significance,
* Correspondence: isinakyar@gmail.com

atypical squamous cells of high significance, lowgrade squamous intraepithelial lesions, and high-grade
squamous intraepithelial lesions were 1.07%, 0.07%,
0.3%, and 0.17%, respectively (5). These rates are lower
than those reported in Europe and North America, which
may be due to sociocultural differences and the lack of a
national screening program in Turkey (5). Although the
conventional Papanicolaou (Pap) test complements HPV
DNA testing, some data suggest that a single baseline HPV
DNA test is more sensitive than a single conventional Pap
test (7–10). HPV are typed according to their L1 capsid
gene sequence differences (11). More than 150 HPV types
known to occur have been categorized (12). Most of the
HPV infections (80%) are temporary and are generally
cleared by the immune system, without any clinical signs,
within 6–12 months (5). Persistence of a high-risk infection
is a risk factor for the development of cervical cancer (13).
The intermediate types generally infect the skin or genital
region (11,14). Benign condylomata are not precursors of
malignant carcinomas (15). The high-risk group includes
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 68, 73,
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and 82; the intermediate group includes types 26 and 66;
and the low-risk group includes types 6, 11, 40, 42, 43, 44,
54, 61, 70, 72, 81, and 83 (11,14).
Because HPV genotype information is useful clinically
for follow-up and prognosis, the detection of oncogenic
HPV genotypes is generally proposed (16). Because HPV
16 causes approximately 50%–60% of all cervical cancers
and HPV 18 causes 15%–20%, they should be determined
in women infected with oncogenic HPV to identify those
at greater risk of developing cervical cancer (6,17–22). The
prevalence of HPV infection and high-risk HPV types
varies among different populations. The HPV test is not
used for cervical cancer screening in Turkey, and there is
limited information about HPV prevalence and the prevalence of HPV genotypes. Few data are available regarding
HPV prevalence in Turkey, which is 2%–6% in the female
population (23–26). The frequency of HPV DNA positivity according to age group was striking; those between 17
and 30 years showed a prevalence of 38%, and this rate
lowered to 5.1% in the over-55-year-old female population
in Turkey (27).
The aim of this study was to evaluate the prevalence
of HPV infection in women between 15 and 68 years of
age in categorized age groups in Turkey to determine the
prevalence of particular HPV genotypes and to examine
whether there was a correlation between molecular and
cytological results.
2. Materials and methods
2.1. Study design
In this study cervical samples were collected according
to liquid-based cytology technology. In this method, the
cervical cells are immersed in a conserving liquid before
being fixed on the slide, which prevents desiccation and
reduces the quantity of obscuring material (28). A total
of 35,685 liquid-based samples collected from women
attending the gynecological outpatient clinics of 6 hospitals
for regular gynecological monitoring between 2007
and 2010 were analyzed. The samples collected between
2007 and 2010 from 1014 patients who were positive
cytologically and who had a family history of cervical
cancer were included in this retrospective analysis. The
women were between 15 and 68 years of age. A nested
multiplex PCR assay using GP5/GP6 primers was used.
No personal information of the patients was included in
the study; therefore, informed consent was not needed.
Our university’s ethics committee approved this study (no.
2010/84; 22.07.2010).
2.2. Sample preparation
The samples were prepared using liquid-based cytology
techniques (ThinPrep; Cytyc Corporation, Boxborough,
MA, USA) and the Liqui-PREPT system (LGM
International Inc., Melbourne, FL, USA), and the slides
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were stained with Pap. The Bethesda System (TBS) 2001
was used for cytological classification (29). The following
terminology was used in this study: “cytologically
negative” was used in place of “negative for intraepithelial
lesion or malignancy”. “Cytologically positive” was used
for “squamous cell abnormalities”, including “atypical
squamous cells of undetermined significance”, atypical
squamous cells, cannot exclude “high-grade squamous
intraepithelial lesion”; “low-grade squamous intraepithelial
lesion”; and “high-grade squamous intraepithelial lesion”.
After the preparation of standard slides, residual samples
were placed in tubes with 0.9% saline, stored at –20 °C, and
delivered to the molecular microbiology laboratory.
2.3. HPV DNA detection and genotyping
Detection and genotyping of HPV was performed using
PCR and DNA sequence analysis with a sequence analyzer,
which is a fluorescence-based capillary electrophoresis
system.
2.3.1. DNA preparation
Liquid-based cervical samples (5 mL) were collected in
Falcon tubes. They were centrifuged at 4500 rpm for 5
min. The 200-µL pellet was added to a 1.5-mL tube and
extracted by QIAamp DNA Mini Kit (QIAGEN, Hilden,
Germany) according to the manufacturer’s instructions.
2.3.2. PCR procedures
PCR cycles were performed in a final volume of 50 μL.
Each PCR mixture contained 50 mM KCl, 10 mM TrisHCl (pH 8.5), 6 mM MgCl2, a 200 μM concentration of
each dNTP, 5 U (instead of 7–10 U) of AmpliTaq Gold
DNA polymerase (PE Applied Biosystems, Weiterstadt,
Germany), 50 pmol of primers MY09 and MY11, 5 pmol of
primer HMBB01, and 5 pmol of primers PC04 and GH20
for the simultaneous amplification of a 248-bp product of
the human β-globin housekeeping gene. Amplifications
were performed with AmpliTaq Gold activation. PCR
cycles with primers GP5+ and GP6+ were performed
as described in the original publication with 2 minor
modifications, which are indicated parenthetically below
(10). To increase the sensitivity of HPV detection, nested
PCR cycles were performed using MY09-MY11 as outer
and GP5+-GP6+ as inner primers. Two microliters of the
MY09-MY11 PCR product was used as a template for the
nested PCR amplification with GP5+-GP6+ primers. Two
microliters of the PCR product served as a template for
the nested PCR cycles. Ten microliters of the amplification
products were analyzed by electrophoresis on 2% agarose
gels and SYBR green nucleic acid gel stain.
2.3.3. Sequencing of PCR products
PCR products were sequenced by the MegaBACE 750
(Leipzig, Germany) using 5 pmol of either forward or back
primers.
The primers used in this study are listed in Table 1 (30).
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Table 1. Primers used in the study.
Type

Primers

Outer primers

MY09 and MY11 primer cocktail is used [28]

Inner and sequence primers

Human β-globin housekeeping gene (248-bp)

GP5+

5ʹ-TTT GTT ACT GTG GTA GAT ACT AC-3ʹ

GP6+

5ʹ-GAA AAA TAA ACT GTA AAT CAT ATT C-3ʹ

HMBB01 5ʹ-GCG ACC CAA TGC AAA TTG GT-3ʹ
PC04
5ʹ-GAA GAG CCA AGG ACA GGT AC-3ʹ
GH20
5ʹ-CAA CTT CAT CCA CGT TCA CC-3ʹ

3. Results
Of 1014 examined samples, cytological diagnosis was
negative in 459 (45.3%), atypical squamous cells of undetermined significance were found in 369 (36.4%), atypical
squamous cells of high significance in 3 (0.3%), low-grade
squamous intraepithelial lesions in 170 (16.8%), and highgrade squamous intraepithelial lesions in 13 (1.3%). A total of 706/1014 (69.6%) samples were HPV DNA-positive
and were typed by DNA sequencing. The prevalence and
distribution of HPV types according to cytological diagnostic categories are given in Table 2.
The most common types of HPV detected were 16, 6,
18, 31, 66, 56, 53, 81, 45, and 62 with prevalences of 14.2%,
8.8%, 5.5%, 4.5%, 3.8%, 3.3%, 2.6%, 2.3%, 2.2%, and 2.1%,
respectively.
High-risk HPV types were detected in 484 (47.7%)
samples, and the 5 most common ones were HPV 16
(14%), 18 (5.5%), 31 (4.5%), 56 (3.3%), and 53 (2.6%).
A total of 181 samples contained low-risk HPV types;
the 5 most common ones were HPV 6 (8.8%), 81 (2.3%),
11 (1.7%), 90 (1.0%), and 83 (0.9%). Finally, 38 samples
were classified into the intermediate risk group, and there
was only 1 type detected in this group, type 66 (3.8%).
HPV DNA was detected in 63.0% of cytologically
negative and 75.1% of cytologically positive samples.
To demonstrate the discrepancy between cytologically
negative and positive groups, the McNemar paired
proportion test was used. The difference between the
459 cytologically negative and 555 cytologically positive
samples was 17.6% (95% confidence interval, 13.7%–
21.2%), and it was statistically significant (P < 0.0001).
HPV DNA type analysis according to cytologic diagnostic
category is given in Table 3.
The prevalence of high-risk HPV types according to
age was also examined in this study. Of the 484 detected
HPV cases of any type, 57% were in women aged 25–34
years and 31% were in women 35–44 years old.
The types of high-risk HPV found in the 25–34 age
group was, in order of prevalence, types 16, 18, 31, 56, 53,

45, 58, 62, 59, 67, 51, 35, 73, 39, 33, 68, 82, 52, and 86.
The types of high-risk HPV in the 35–44 age group was, in
order of prevalence, types 16, 18, 31, 56, 51, 53, 59, 62, 52,
45, 58, 67, 73, 39, 33, 35, and 68. The prevalence of highrisk types according to age is shown in Table 4.
4. Discussion
While HPV screening is not routinely practiced in
Turkey, the findings of this study do not reflect HPV
screening results in Turkey, but rather show the results
of a selected risk group (patients with positive cytology,
family history, and physician order) that underwent HPV
testing. In this study 2 methods were used in combination:
cytological examination and HPV DNA detection by PCR,
followed by DNA sequence analysis. The main cytological
classification was performed according to TBS 2001. In
total, 1014 samples were examined, of which 170 (16.8%)
were both cytologically and HPV DNA PCR-negative. Of
459 cytologically negative and 555 cytologically positive
samples, 289 (63.0%) and 417 (75.1%) were HPV DNApositive, respectively. HPV positivity was most common in
the high-risk group (47.7%), followed by the low (17.9%),
and intermediate (3.8%) risk groups, according to HPV
type classification. Of the 1014 samples evaluated in this
study, 484 were infected with HPV. The 3 most common
HPV types detected were types 16 and 18 (high risk group)
and type 6 (low risk group).
The most prevalent high-risk HPV types were 16
(14.2%), 18 (5.5%), 31 (4.5%), 56 (3.3%), 53 (2.6%), 45
(2.2%), 62 (2.1%), 58 (2.0%), 59 (1.8%), 67 (1.6%), 51
(1.6%), 35 (1.2%), 73 (1.2%), 52 (1.1%), 33 (0.9%), 39
(0.9%), 68 (0.7%), 82 (0.4%), and 86 (0.2%).
In another study in Turkey in which the presence of
HPV-DNA was analyzed, 356 cervical smear samples were
examined by 2 different methods, MY09/11 consensus
real-time polymerase chain reaction (RT-PCR) and typespecific RT-PCR. Frequencies of detection of high-risk
HPV types in the HPV-positive samples were as follows:
HPV-16, 32 (33.7%); HPV-52, 12 (12.6%); HPV-58, 11
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Table 2. The prevalence and distribution of HPV according to risk group in different cytological diagnostic categories.
Cytologically
negative

ASC-US

ASC-H

LSIL

HSIL

Total

Type 16

47

48

1

41

7

144 (14.2%)

Type 31

16

20

-

10

-

46 (4.5%)

Type 18

28

17

-

10

1

56 (5.5%)

Type 56

16

7

-

10

-

33 (3.3%)

Type 51

1

5

-

10

-

16 (1.6%)

Type 53

6

12

-

8

-

26 (2.6%)

Type 52

4

3

-

3

1

11 (1.1%)

Type 45

7

11

-

4

-

22 (2.2%)

Type 62

9

7

-

5

-

21 (2.1%)

Type 58

6

8

-

5

1

20 (2.0%)

Type 59

9

5

-

4

-

18 (1.8%)

Type 67

6

6

-

4

-

16 (1.6%)

Type 35

5

6

-

1

-

12 (1.2%)

Type 73

7

3

-

1

1

12 (1.2%)

Type 33

2

4

-

3

-

9 (0.9%)

Type 39

3

4

-

2

-

9 (0.9%)

Type 68

5

2

-

-

-

7 (0.7%)

Type 82

1

2

-

-

1

4 (0.4%)

Type 86

1

1

-

-

-

2 (0.2%)

Total sum of HPV type (high-risk)
Total sum of HPV type
(intermediate-risk): type 66
HPV type (low-risk)

179 (17.7%)

171 (16.9%)

1 (0.1%)

121 (11.9%)

12 (1.2%)

484 (47.7%)

13 (1.3%)

9 (0.9%)

-

16 (1.6%)

-

38 (3.8%)

Type 6

48

27

-

13

-

88 (8.8%)

Type 81

12

8

-

3

-

23 (2.3%)

Type 11

10

4

-

2

1

17 (1.7%)

Type 90

5

3

-

2

-

10 (1.0%)

Type 83

3

5

-

1

-

9 (0.9%)

Type 84

2

5

-

1

-

8 (0.8%)

Type 54

5

3

-

-

-

8 (0.8%)

Type 61

3

2

-

-

-

5 (0.5%)

Type 43

3

-

1

-

4 (0.4%)

Type 87

2

-

1

-

3 (0.3%)

Type 55

1

-

-

-

2 (0.2%)

Type 74

2

-

-

-

2 (0.2%)

HPV type (high-risk)

Type 91

1
1

-

-

-

1 (0.1%)

Type 40

1

-

-

-

-

1 (0.1%)

Total sum of HPV type (low-risk)

97 (9.6%)

59 (5.8%)

0

24 (2.4%)

1 (0.1%)

181 (17.9%)

HPV-positive (undetermined-type)

-

3 (0.3%)

-

-

-

3 (0.3%)

Total sum of HPV-positive patients

289 (28.5%)

242 (23.9%)

1 (0.1%)

161 (15.9%)

13 (1.3%)

706 (69.6%)

Total sum of HPV-negative patients

170 (16.8%)

127 (12.5%)

2 (0.2%)

9 (0.9%)

0

308 (30.4%)

Total

459 (45.3%)

369 (36.4%)

3 (0.3%)

170 (16.8%)

13 (1.3%)

1014

ASC-US: atypical squamous cells of undetermined significance, HSIL: high-grade squamous intraepithelial lesion, ASC-H: atypical squamous
cells of high significance, LSIL: low-grade squamous intraepithelial lesion, HSIL: high-grade squamous intraepithelial lesion.
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Table 3. HPV DNA type analysis according to cytologic diagnostic category.

HPV DNA type analysis

Cytologic diagnostic category
Negative

Positive

Total

Negative

170

138

308

Positive

289

417

706

Table 4. The prevalence of high-risk types according to age.

Type (high-risk)

Age
15–24 years

25–34 years

35–44 years

45–54 years

55–68 years

Total

16

8

84

46

5

1

144 (29.8%)

18

9

32

13

2

0

56 (11.6%)

31

4

27

13

1

1

46 (9.5%)

56

1

18

11

3

0

33 (6.8%)

53

0

15

8

3

0

26 (5.4%)

45

0

15

6

1

0

22 (4.5%)

62

0

11

7

3

0

21 (4.3%)

58

2

12

6

0

0

20 (4.1%)

59

0

10

8

0

0

18 (3.7%)

51

0

7

9

0

0

16 (3.3%)

67

1

8

5

2

0

16 (3.3%)

35

2

7

3

0

0

12 (2.5%)

73

0

7

5

0

0

12 (2.5%)

52

1

3

7

0

0

11 (2.3%)

39

0

5

4

0

0

9 (1.9%)

33

0

5

4

0

0

9 (1.9%)

68

0

5

2

0

0

7 (1.4%)

82

0

4

0

0

0

4 (0.8%)

86

0

2

0

0

0

2 (0.4%)

Total

28 (5.8%)

277 (57.2%)

157 (32.4%)

20 (4.1%)

2 (0.4%)

484

(11.6%); HPV-18, 7 (7.4%); HPV-31, 7 (7.4%); HPV-35,
7 (7.4%); HPV-68, 6 (6.3%); HPV-33, 4 (4.2%); HPV-82,
4 (4.2%); HPV-39, 3 (3.2%); and HPV-45, 2 (2.1%) (31).
In this study, types 52 and 58 are more prevalent than type
18, which is different from the results of our study and
the studies we compared our study with. This may be due
to the different methods used, lower quantity of patients
analyzed, and the period of analysis.

The prevalence of specific HPV types worldwide
shows variation according to geographical differences.
For example, in East Asia the most common HPV types in
invasive cervical cancer were types 16, 18, 52, and 54, with
prevalences of 57.1%, 17%, 11.4%, and 8.5%, respectively
(32). In addition, according to a study in China, the
most common and persistent high-risk HPV types were
16 (18.21%), 58 (13.2%), 18 (8.66%), 52 (7.06%), and 33
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(6.78%). Their results showed that 45.6% of women were
infected with HPV in China (33).
Additionally, HPV infection in Spain was detected in
43.2% of women between 15 and 75 years (34).
In Italy, it was determined that 35.9% of women between
the ages of 15 and 54 were HPV-positive (35). In Turkey,
the HPV infection rate is 2%–6%. As in this study, global
results demonstrated that HPV 16 was the most prevalent
infection (28%), whereas HPV 18 was found more rarely
(34). For example, in Venezuela HPV 16 was the most
common type (60%), followed by HPV 18 (20%), HPV
6 (10%), and HPV 58 (10%) (36). With the exception of
East Africa, China, Japan, and Taiwan, HPV 16 is the most
prevalent type in all parts of the world (34). Interestingly,
HPV type 18 is detected at the same frequency all over
the world. In the Chinese study mentioned above, type
18 (8.6%) was detected most frequently after type 16 (33).
Type 18 was detected at a rate of 8% in the Madrid study
mentioned above (34). In Turkey, according to our study,
type 18 was detected at a rate of 5.5%. In our study, type
31 was the third most common genotype (4.5%), which
was similar to rates determined in a previous Italian study
(35). On the contrary, in China this type was detected in
less than 6% of HPV infections, and type 58 (13.2%) was
the second most frequent type (33). However, in our study
type 58 was detected at a rate of 2.0% in contrast to the
commonly detected types; certain HPV types are more
frequently observed in some parts of the world than in
others. HPV type 35 is detected at a rate of 1.2% in our
study, but, interestingly, it is not even mentioned in the
studies from other Mediterranean regions, such as Madrid
or North Sardinia (34,35). In some parts of Italy and
Spain, HPV type 53 was the second most common type;
however, as in this study, in Mediterranean countries such
as Turkey and Greece, it is not as common (2.6%) (33,35).
In this study, as shown in Table 2, nearly a third (30%) of
HPV-positive samples were found in patients with normal
cytology. Although this rate is lower in some parts of
Europe, a study from Madrid showed similar results (34).
This high prevalence of HPV in women with normal
cytology might originate from women who had abnormal
Pap tests attending a specialized gynecology unit for
cervical pathology. Alternatively, such cytologically
negative but HPV DNA-positive samples may indicate
early-phase infection with no significant morphological
change.
Detected HPV genotypes can be different according
to cytologic diagnostic category. In normal cytology
samples from our study, HPV 16 was the most common
high-risk genotype (10.2%), followed by HPV 18 (6.1%).
However, in atypical squamous cells of undetermined
significance, although HPV type 16 was still the most
common high-risk genotype (13.0%), type 31 was the

968

second most common type, and type 18 was the third most
common genotype (4.6%). In the high-grade squamous
intraepithelial lesion category the most frequent type was
type 16 (54%), followed by 18, 52, 58, and 73 (7.7%). In
this group, type 16 was again the most common high-risk
genotype. These results are different than the results found
in Spain, another country in the Mediterranean region
(34). In normal cytology samples in Spain, although HPV
16 was the most common high-risk genotype (21%), type
53 was the second (16%) most common type. In atypical
squamous cells of undetermined significance, although
HPV type 16 was still the most common high-risk
genotype (30%), type 53 was the second most common
type, and type 31 was the third most common genotype
(11.3%). In the high-grade squamous intraepithelial lesion
category the most frequent type was 16 (50.6%) followed
by 52 (13.9%), 31 (11.4%), and 33 (10.1%). In this group,
type 16 was again the most common high-risk genotype.
As shown in Table 3, of the 555 samples that were
positive cytologically, 138 (24.9%) were HPV DNAnegative and 417 (75.1%) were positive for HPV DNA.
This distribution may indicate early-phase infection, at
which point no morphological change has occurred.
The HPV types were similar in the 25–34 and 35–44 age
groups. In another study in Turkey, HPV DNA positivity
was detected in 38% of the female population between
17 and 30 years and in 5.1% of women over 55 years old
(28). HPV-positive women were commonly found to
be sexually active and of childbearing age. As is shown
in Table 4, in the early age group (15–24), as well as the
25–34 and 35–44 age groups, type 18 was the second most
frequently detected type. However, in the 45–54 age group
it was the fifth most frequent type. Thus, its frequency
decreased with age. Another interesting aspect of HPV
type 18 is that its presence was significantly associated
with adenocarcinoma and lymphatic metastasis (P < 0.05).
Furthermore, HPV 18 persistence was associated with a
cervical cancer prognosis (P < 0.0001) (33).
Recently, multiple HPV infections have been examined
because with the development of HPV vaccines that do
not cover all genotypes the distribution of infection with
types not covered by vaccines could be impacted; the
elimination of one HPV type could affect the natural
history of the remaining genotypes. Therefore, obtaining a
solid knowledge of genotype HPV distribution is becoming
increasingly critical (34). As expected, a proportion of the
patients in this study probably had multiple infections. It
was not possible to detect more than one infecting agent
based on the methods used in this study. HPV DNApositive patients were typed according to their DNA
sequences. Therefore, only the most prevalent type was
likely reported. The HPV prevalence data in this study
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differed from other study results in Turkey, as well as results
from other countries, likely because our patients were
referred by their gynecologists due to suspicion of HPV
infection upon physical examination. However, the HPV
types we report here are generally similar to the worldwide
distribution, although a few different types, such as 66,
56, and 53, were common in samples from this study.
The McNemar paired proportion test results of this study
indicated that the 2 methods used differed significantly (P
< 0.0001), suggesting that they are complementary. This
result supports the use of our protocol, suggesting that the
combined use of cytological and molecular typing methods
yields a more precise result. The conventional Pap smear is
the most effective cervical cancer-screening test, and PCR
is a sensitive method for detecting and genotyping HPV
DNA in normal and abnormal ThinPrep samples. This
technique is extremely useful for routine investigation and
facilitates better patient clinical management. Combining

molecular testing with morphology analysis for cervical
screening increased the sensitivity and reliability of HPV
detection and typing.
The importance of treatment and prophylaxis for HPV
can clearly be recognized when the 493,000 new cases of
cervical cancer and 274,000 deaths per year are taken into
consideration. The main strategy should be to develop
prophylactic and therapeutic vaccines (37).
In conclusion, this study confirmed the high prevalence
of HPV infection in Turkey and highlighted regional
differences according to risk genotypes. Moreover, this
study provides an important database for future research
studies due to its wide patient spectrum.
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